Han R, et al. - Researchers sought to determine the prevalence of hepatitis C infection among the general population and high-risk groups. From Medline and Embase, they included 46 relevant studies in the European Union/European Economic Area (EU/EEA) from 2015 to 2018. As per analysis, the anti-hepatitis C virus (HCV) prevalence was heterogeneous across different population groups in EU/EEA. People who inject drugs had the highest prevalence of anti-HCV (range of 7.90–82.00%), followed by prisoners (7.00–41.00%), HIV-positive men who have sex with men (MSM) (1.80–7.10%), HIV-negative MSM (0.20–1.80%), pregnant women (0.10–1.32%) and first-time blood donors (0.03–0.09%). Further, European countries showed a wide variation in the prevalence ranging from 0.54 to 1.50%.